| Trial ID # | NCT01363232 |
| Phase | I |
| Drug Class | Signaling Pathway Inhibitors: RAS-RAF-MEK-ERK/MEK |
| Drug Name | Binimetinib |
| Alternate Drug Names | MEK162, MEK inhibitor MEK162, ARRY-162, ARRY-438162, Mektovi |
| Drugs in Trial | Binimetinib, Buparlisib |
| Eligible Participant | Advanced solid tumors with RAS or RAF alterations |
| Patients Enrolled | 89, median 3 prior therapies (1-12); 19 ovarian |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, PFS, RP2D, evaluated per RECIST |
| Biomarkers | KRAS, NRAS, BRAF alterations |
| Efficacy | RP2D: 80 mg buparlisib qd+45 mg binimetinib bid ovarian patients at RP2D: |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | Binimetinib+buparlisib shows encouraging efficacy in RAS/RAF MUT ovarian cancer patients, but with significant toxicity |
| Reference | Bardia A et al. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. Oncologist (2020) 25(1):e160-e169 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.